Drug delivery companies develop technologies, formulations and platforms that control how, where and when therapeutic agents are released in the body. The field focuses on improving treatment efficacy, reducing side effects and helping medicines reach their intended targets safely and efficiently.
This category includes companies working on:
Browse 119 UK drug delivery companies below.
ML-enabled nanoparticle delivery platform for targeted therapeutics
Vector Bioscience is a University of Cambridge spin-out developing a machine learning-enabled drug delivery platform based on metal-organic framework nanoparticles. The technology provides cargo-agnostic, targeted delivery of oligonucleotides and small molecules with controlled release, initially focused on…
Tumour-activated peptide drug conjugates for targeted oncology
Avacta Therapeutics is a clinical-stage biotechnology company developing peptide drug conjugates designed to deliver toxic chemotherapy payloads selectively within the tumour microenvironment. The company's delivery approach uses a short engineered peptide that masks the active payload until it is cleaved by…
Targeted nanoparticles for in vivo CAR-T and gene delivery
Deliver Biosciences is a biotechnology company developing targeted nanoparticle vectors for in vivo cell and gene therapies. Its delivery platform transports genetic payloads, including DNA and mRNA, into selected cell types using programmable targeting components. Its lead programme aims to engineer T cells inside…
Circadian hormone therapeutics for rare endocrine conditions
Neurocrine UK is the European operations of Neurocrine Biosciences, a Cardiff-headquartered specialty pharmaceutical company developing and commercialising hormone therapeutics for rare and chronic endocrine conditions. The company's scientific approach centres on circadian-based formulation technology, designed to…
National innovation centre accelerating drug discovery
Medicines Discovery Catapult (MDC) is an independent, not-for-profit national innovation centre that supports UK medicines discovery organisations across the full drug discovery pipeline. MDC provides access to specialist laboratory technologies, computational and AI-driven tools, translational R&D expertise, and…
Nanoparticle platform for targeted genetic medicine delivery
ViaNautis is a nanomedicine company developing a polymer nanoparticle platform for the targeted intracellular delivery of genetic therapeutic payloads across difficult-to-penetrate biological barriers. The platform is designed to encapsulate a broad range of genetic cargoes and guide them to specific tissues and cell…
DNA-based gene therapy platform for intercellular therapeutic gene delivery
Bitrobius Genetics is a UK biotech developing a novel DNA-based gene therapy platform technology designed to deliver functional copies of mutated genes to cells within a target tissue or organ. Its platform is based on the principle of DNA replication and intercellular transmission, aiming to achieve broad tissue…
Inhaled antifungal therapies for serious respiratory fungal infections
Pulmocide is a late-stage biopharmaceutical company developing inhaled medicines for life-threatening respiratory fungal infections. Its lead compound opelconazole is a triazole antifungal designed for inhaled delivery to maximise pulmonary drug concentration while minimising systemic exposure and drug interactions.…
Inhalation and nasal drug product development and manufacturing CDMO
Bespak is a contract development and manufacturing organisation specialising in inhaled and nasal drug delivery. It supports pharmaceutical companies from feasibility, formulation and analytical development through clinical supply to commercial-scale manufacturing and fill-finish of pressurised metered dose inhalers.…
Clinical-stage company developing radioligand cancer therapies
Blue Earth Therapeutics is a clinical-stage biotechnology company developing targeted radiopharmaceutical therapies for cancer. Its pipeline centres on prostate-specific membrane antigen-targeted radioligand therapies using both beta- and alpha-emitting radionuclides, designed to deliver high radiation doses to tumour…
Synthetic T cell-priming vaccines and immunotherapies for infectious disease
Gylden Pharma is a clinical-stage biotechnology company developing 100% synthetic T cell-priming vaccines and immunotherapies. Its nanoparticle platform delivers synthetic peptides that stimulate cellular immune responses against intracellular pathogens, providing strain-agnostic protection without cold-chain…
Engineered bacterial immunotherapies for solid tumours
Prokarium is a clinical-stage biopharmaceutical company developing microbial immunotherapies using engineered Salmonella strains. Its platform combines synthetic biology with AI-enabled discovery to create programmable bacterial therapeutics that deliver payloads within the tumour microenvironment. The lead programme…
Injectable biomaterial gel to treat degenerative disc disease
Orthoson is a medtech company developing micro-invasive injectable treatments for chronic back pain caused by degenerative disc disease. Its lead product, a patented pNIPAM-DMAc co-polymer hydrogel, is designed to be injected into the intervertebral disc, where it gels in-situ to restore the mechanical and biological…
Clinical-stage antibody-drug conjugate specialist targeting solid tumours
Pheon Therapeutics is a clinical-stage biotechnology company developing a pipeline of antibody-drug conjugates for the treatment of solid tumours. The company combines monoclonal antibodies with proprietary cytotoxic payloads and linker technologies, taking a target-specific approach to optimising each construct for…
Sterile injectable drug manufacturing and fill-finish for global pharma
Patheon is a contract development and manufacturing site operating as part of Thermo Fisher Scientific's Pharma Services business. The site specialises in sterile liquid and freeze-dried injectable products, including high potency medicines and large volume parenterals, offering development, commercial manufacturing,…
Novel antibiotic-sparing therapeutics for chronic wound care
ONYA Therapeutics is a biotechnology company developing novel pharmaceutical treatments for acute and chronic wounds. The company's pipeline centres on a patented controlled-release drug delivery technology designed to manage wound exudate and reduce reliance on antibiotics, addressing antimicrobial resistance in…
Specialty pharmaceuticals for Parkinson's disease and related neurological conditions
Britannia Pharmaceuticals is a UK-based specialty pharmaceutical company developing and marketing treatments for Parkinson's disease and related conditions including psychosis. The company's product range includes apomorphine-based therapies available in multiple delivery formats, alongside clozapine-based treatment…
Engineered iPSC-derived exosomes for tissue-targeted drug delivery
Excellio Labs is a biotech developing engineered exosome platforms for targeted drug delivery. The technology exploits the inherent tissue-specificity of iPSC-derived extracellular vesicles, which are further surface-modified to create precision drug carriers capable of delivering nucleic acids, proteins, and small…
Hydrogel capsule platform for weight loss and oral drug delivery
Oxford Medical Products is developing a gastroretentive hydrogel platform with two applications. The technology is a swallowable dual-polymer capsule that expands in the stomach to suppress appetite without pharmacological intervention; a Phase 2a clinical trial is underway following positive Phase 1 results. Oxford…
AI-driven delivery platform for siRNA therapies beyond the liver
Undecimal Bio is a biotechnology company developing targeted delivery technologies for small interfering RNA (siRNA) therapeutics beyond the liver. Its DELiveri platform combines large-scale combinatorial chemistry, functional cell-based screening and AI to identify synthetic conjugates that transport siRNA into…